ストックスクリーナーアプリを入手
18.92
4.92%
-0.98
アフターアワーズ：
18.92
前日終値:
$19.90
開ける：
$19.66
24時間の取引高:
1.09M
Relative Volume:
0.44
時価総額：
$2.09B
収益：
$70.92M
当期純損益:
$-342.21M
株価収益率:
-5.026
EPS:
-3.7644
ネットキャッシュフロー:
$-304.30M
1週間 パフォーマンス:
-1.82%
1か月 パフォーマンス:
+2.99%
6か月 パフォーマンス:
-42.67%
1年 パフォーマンス:
+7.99%
1日の値動き範囲:
$18.89
$19.90
1週間の範囲:
$18.89
$20.10
52週間の値動き範囲:
$13.18
$34.29
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Compare VRDN vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
18.92 | 2.18B | 70.92M | -342.21M | -304.30M | -3.7644 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-10 | 繰り返されました | Wedbush | Outperform |
| 2025-12-03 | 開始されました | William Blair | Outperform |
| 2025-11-24 | 開始されました | Truist | Buy |
| 2025-08-25 | 再開されました | Jefferies | Buy |
| 2024-12-19 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-11-25 | 開始されました | TD Cowen | Buy |
| 2024-09-11 | 繰り返されました | Needham | Buy |
| 2024-06-11 | 開始されました | Wolfe Research | Outperform |
| 2024-06-06 | 開始されました | Goldman | Buy |
| 2024-05-09 | ダウングレード | B. Riley Securities | Buy → Neutral |
| 2024-05-09 | ダウングレード | Ladenburg Thalmann | Buy → Neutral |
| 2023-06-14 | 開始されました | BTIG Research | Buy |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-05-30 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-04-17 | 開始されました | Wells Fargo | Overweight |
| 2023-03-30 | 開始されました | Stifel | Buy |
| 2022-12-19 | 開始されました | Cowen | Outperform |
| 2022-12-19 | 開始されました | Needham | Buy |
| 2022-12-16 | 開始されました | Credit Suisse | Outperform |
| 2022-12-01 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-23 | 開始されました | B. Riley Securities | Buy |
| 2021-11-18 | 開始されました | SVB Leerink | Outperform |
| 2021-10-12 | 開始されました | Evercore ISI | Outperform |
| 2021-01-25 | 開始されました | Ladenburg Thalmann | Buy |
すべてを表示
Viridian Therapeutics Inc (VRDN) 最新ニュース
Viridian Therapeutics Inc (VRDN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Viridian Therapeutics Market Sentiment - Benzinga España
Viridian Therapeutics Inc (VRDN) Institutional Confidence - TradingKey
Viridian Therapeutics Inc (VRDN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viridian Therapeutics Inc (VRDN) Income Statement - TradingKey
Viridian Therapeutics Inc (VRDN) Balance Sheet - TradingKey
Viridian Therapeutics Inc (VRDN) Cash Flow - TradingKey
Viridian Therapeutics, Inc. Revenue Breakdown – NASDAQ:VRDN - TradingView
Viridian Therapeutics Inc (VRDN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Viridian Therapeutics Inc (VRDN) Valuation: PE, PB & Fair Value Analysis - TradingKey
VRDN|Viridian Therapeutics Inc|Price:19.270|Chg%:+0.010 - TradingKey
VRDN|Viridian Therapeutics Inc|Price:19.965|Chg%:+0.695 - TradingKey
Viridian Therapeutics Inc (VRDN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Viridian Therapeutics stock trades around recent lows as cash runway and thyroid eye trial data shap - Ad-hoc-news.de
FDA approves veligrotug-vvze (Lumvoa) for thyroid eye disease across active and chronic stages - Ophthalmology Times Europe
VRDN|Viridian Therapeutics Inc|Price:19.247|Chg%:-0.013 - TradingKey
Price-Driven Insight from (VRDN) for Rule-Based Strategy - Stock Traders Daily
Wells Fargo Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Wells Fargo Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN) - The Globe and Mail
Viridian Therapeutics (VRDN) Stock Analysis: A Biotech Gem with Nearly 95% Upside Potential - DirectorsTalk Interviews
Viridian Therapeutics (VRDN) Goldman Sachs 46th Annual Global Healthcare Conference summary - Quartr
Lumvoa’s Unique Profile Leads to Optimism Around Viridian Therapeutics (VRDN) - Yahoo Finance
Viridian Therapeutics (VRDN) Rebounds Sharply, Is The Valuation Still Too Rich? - Yahoo Finance
Viridian Therapeutics (VRDN) Stock Still Looks Above Fair Value Today - Yahoo Finance
VRDN6389238 Bond Coupon Profile — Rate & Payments - TradingView
VRDN6389238 Bond Profile — Key Metrics - TradingView
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Viridian Therapeutics, Inc. (VRDN) Reports Q3 Loss, Tops Revenue Estimates - MSN
Viridian Therapeutics (VRDN) Could Be 87% Below Fair Value After FDA Approval - Sahm
Tangible book value per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Total assets of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Price to book ratio of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Operating cash flow per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Total debt per share of Viridian Therapeutics, Inc. – HAM:1S1 - TradingView
Viridian Therapeutics outlines eye disease strategy as Nasdaq-listed biotech builds its pipeline - ad-hoc-news.de
Viridian Therapeutics (VRDN) Declines Sharply as Biotech Sector Faces HeadwindsSell Signal Alerts - Bölüm Sonu Canavarı
Viridian Therapeutics to Participate in Upcoming June Investor Conferences - AOL.com
The Bull Case For Viridian Therapeutics (VRDN) Could Change Following FDA Approval Of Lumvoa For Thyroid Eye Disease - Sahm
Viridian Therapeutics updates pipeline plans as thyroid eye disease program advances - AD HOC NEWS
Wedbush Sees Commercial Edge for Viridian (VRDN) After FDA Milestone - Yahoo Finance
VRDNViridian Therapeutics Inc Options - Finviz
If You Invested $1,000 in Viridian Therapeutics Inc (VRDN) - Stock Titan
Viridian Therapeutics (VRDN) director receives 32,341 stock options at $18.48 strike - Stock Titan
Director Ajer granted 32,341 Viridian Therapeutics (VRDN) stock options at $18.48 - Stock Titan
Viridian Therapeutics (VRDN) director-linked funds receive 32,341 options - Stock Titan
Viridian Therapeutics (VRDN) director receives 32,341 options at $18.48 - Stock Titan
Fairmount-linked entities receive 32,341 Viridian (VRDN) stock options at $18.48 - Stock Titan
VRDN Stock Jumps 6% After-Hours As Viridian Wins First FDA Approval - Stocktwits
VRDN Stock Rises 6.3% in a Week: Here's What You Need to Know - The Globe and Mail
Rx Rundown: Zymeworks, Viridian Therapeutics, BioCryst and more - Medical Marketing and Media
Viridian Therapeutics, Inc. (VRDN) Discusses FDA Approval and Launch Plans for Lumvoa as a New Therapy for Thyroid Eye DiseaseSlideshow (NASDAQ:VRDN) 2026-07-01 - Seeking Alpha
Viridian Therapeutics Inc (VRDN) 財務データ
収益
当期純利益
現金流量
EPS
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):